Kyowa Hakko Kirin Schedules Production Of Japan’s Second Antibody Drug
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin of Japan has scheduled 2013 production of an antibody-based leukemia drug still in testing phases, and is beefing up its production capacity to do so. The company is betting on a paucity of drugs based on the technology, so it plans to spend more than $105 million to build a production wing at one of its plants and add to other infrastructure. The company also has an antibody-based drug in the testing phase for treating stomach cancers, but the leukemia is expected to be the first approved if clinical trials proceed as planned. The firm also is developing a similar drug with Astellas Pharma for suppressing the immune system during organ transplants. (Click here for more - a subscription may be required